{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:10:07Z","timestamp":1777417807545,"version":"3.51.4"},"reference-count":23,"publisher":"SAGE Publications","issue":"7-8","license":[{"start":{"date-parts":[[2002,7,1]],"date-time":"2002-07-01T00:00:00Z","timestamp":1025481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2002,7]]},"abstract":"\n BACKGROUND:<\/jats:title>\n Metastatic renal cell carcinoma (MRCC) has been characteristically unresponsive to chemotherapy. In lieu of an effective regimen, interleukin-2 (IL-2) and interferon alfa are considered drugs of choice to treat this cancer. Subcutaneous IL-2 is safe and well tolerated, with a mortality rate <3%.<\/jats:p>\n <\/jats:sec>\n \n OBJECTIVE:<\/jats:title>\n To report a case of cutaneous and hematologic toxicity in a patient treated with IL-2.<\/jats:p>\n <\/jats:sec>\n \n CASE SUMMARY:<\/jats:title>\n \n A 67-year-old woman received radiotherapy and immunotherapy for cancer that had metastasized to the bone and lungs. IL-2 was part of the regimen. After 5 days of treatment with IL-2, the patient developed a hemorrhagic lesion that progressed to toxic epidermal necrolysis, as well as grade 4 pancytopenia. She died 10 days after treatment was begun. At the time of death, leukocytes were 0.3 \u00d7 10\n 3<\/jats:sup>\n \/mm\n 3<\/jats:sup>\n , platelets 10 \u00d7 10\n 3<\/jats:sup>\n \/mm\n 3<\/jats:sup>\n , and hemoglobin 6.8 mg\/dL.\n <\/jats:p>\n <\/jats:sec>\n \n DISCUSSION:<\/jats:title>\n Cutaneous IL-2 adverse effects are frequent, but generally mild and reversible. The adverse hematologic effects are usually transitory and pancytopenia is not frequent. The severity of cutaneous and hematologic toxicity experienced by our patient has rarely been reported.<\/jats:p>\n <\/jats:sec>\n \n CONCLUSIONS:<\/jats:title>\n The use of IL-2 in bedridden patients with performance status >2 must be given on an individualized basis. If radiotherapy over extensive areas of the body is needed, the use of IL-2 must be postponed until radiotherapy is completed.<\/jats:p>\n <\/jats:sec>","DOI":"10.1345\/aph.1a200","type":"journal-article","created":{"date-parts":[[2003,6,4]],"date-time":"2003-06-04T16:21:48Z","timestamp":1054743708000},"page":"1171-1174","source":"Crossref","is-referenced-by-count":14,"title":["Toxic Epidermal Necrolysis Associated with Interleukin-2"],"prefix":"10.1177","volume":"36","author":[{"given":"Angel A Segura","family":"Huerta","sequence":"first","affiliation":[{"name":"Angel A Segura Huerta MD, Consultant, Medical Oncology Department, University Hospital La Fe, Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Tordera","sequence":"additional","affiliation":[{"name":"Pablo Tordera MD, Assistant, Internal Medicine Department, University Hospital La Fe"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana C","family":"Cerc\u00f3s","sequence":"additional","affiliation":[{"name":"Ana C Cerc\u00f3s MD, Pharmacist, Pharmacy Department, University Hospital La Fe"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana L","family":"Yuste","sequence":"additional","affiliation":[{"name":"Ana L Yuste MD, Consultant, Medical Oncology Department, University Hospital La Fe"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"L\u00f3pez-Tendero","sequence":"additional","affiliation":[{"name":"Pedro L\u00f3pez-Tendero MD, Assistant, Medical Oncology Department, University Hospital La Fe"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaspar","family":"Reyn\u00e9s","sequence":"additional","affiliation":[{"name":"Gaspar Reyn\u00e9s MD, Consultant, Medical Oncology Department, University Hospital La Fe"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2002,7,1]]},"reference":[{"key":"bibr1-aph.1A200","volume-title":"SEER cancer statistics review","author":"Kosary CL","year":"1993"},{"key":"bibr2-aph.1A200","first-page":"390","volume":"10","author":"Ritchie AWS","year":"1983","journal-title":"Semin Oncol"},{"key":"bibr3-aph.1A200","doi-asserted-by":"publisher","DOI":"10.1159\/000052353"},{"key":"bibr4-aph.1A200","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198704093161501"},{"key":"bibr5-aph.1A200","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.1993.8.275"},{"key":"bibr6-aph.1A200","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1994.03510360033032"},{"key":"bibr7-aph.1A200","first-page":"989","volume":"78","author":"Ravaud A","year":"1991","journal-title":"Bull Cancer"},{"key":"bibr8-aph.1A200","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(92)90393-G"},{"key":"bibr9-aph.1A200","volume-title":"TNM. Classification of malignant tumours","author":"Sobin LH","year":"1997"},{"key":"bibr10-aph.1A200","doi-asserted-by":"publisher","DOI":"10.1016\/S0094-0143(21)00485-7"},{"key":"bibr11-aph.1A200","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)67215-X"},{"key":"bibr12-aph.1A200","first-page":"42","volume":"22","author":"Yagoda A","year":"1995","journal-title":"Semin Oncol"},{"key":"bibr13-aph.1A200","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19870201)59:3+<647::AID-CNCR2820591313>3.0.CO;2-#"},{"key":"bibr14-aph.1A200","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19950901)76:5<824::AID-CNCR2820760517>3.0.CO;2-N"},{"key":"bibr15-aph.1A200","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.3.688"},{"key":"bibr16-aph.1A200","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1987.03400120074028"},{"key":"bibr17-aph.1A200","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V69.6.1654.1654"},{"key":"bibr18-aph.1A200","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/83.1.56"},{"key":"bibr19-aph.1A200","doi-asserted-by":"publisher","DOI":"10.1002\/path.1711670309"},{"key":"bibr20-aph.1A200","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980815)83:4<797::AID-CNCR25>3.0.CO;2-M"},{"key":"bibr21-aph.1A200","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-199206000-00020"},{"key":"bibr22-aph.1A200","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr23-aph.1A200","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-200107000-00004"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1A200","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1A200","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:05:49Z","timestamp":1777374349000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1A200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,7]]},"references-count":23,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2002,7]]}},"alternative-id":["10.1345\/aph.1A200"],"URL":"https:\/\/doi.org\/10.1345\/aph.1a200","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,7]]}}}